Unveiling the Potential of Purinergic Signaling in Schistosomiasis Treatment

Author(s): Nathália Ferreira Oliveira, Claudia Lucia Martins Silva*

Journal Name: Current Topics in Medicinal Chemistry

Volume 21 , Issue 3 , 2021

Become EABM
Become Reviewer

Graphical Abstract:


Schistosomiasis is a neglected tropical disease. It is related to long-lasting granulomatous fibrosis and inflammation of target organs, and current sub-optimal pharmacological treatment creates global public health concerns. Intravascular worms and eggs release antigens and extracellular vesicles that target host endothelial cells, modulate the immune system, and stimulate the release of damageassociated molecular patterns (DAMPs). ATP, one of the most studied DAMPs, triggers a cascade of autocrine and paracrine actions through purinergic P2X and P2Y receptors, which are shaped by ectonucleotidases (CD39). Both P2 receptor families, and in particular P2Y1, P2Y2, P2Y12, and P2X7 receptors, have been attracting increasing interest in several inflammatory diseases and drug development. Current data obtained from the murine model unveiled a CD39-ADP-P2Y1/P2Y12 receptors signaling pathway linked to the liver and mesenteric exacerbations of schistosomal inflammation. Therefore, we proposed that members of this purinergic signaling could be putative pharmacological targets to reduce schistosomal morbidity.

Keywords: Purinergic signaling, Schistosomiasis, Endothelial cell, Inflammation, Macrophage, Microbiome, Extracellular vesicle, ATP, P2Y receptor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 20 January, 2021
Page: [193 - 204]
Pages: 12
DOI: 10.2174/1568026620666200924115113
Price: $65

Article Metrics

PDF: 17